CSIMarket
 
Merrimack Pharmaceuticals Inc  (NASDAQ: MACK)
Other Ticker:  
 
 
Price: $15.1300 $0.00 0.000%
Day's High: $15.16 Week Perf: 0.2 %
Day's Low: $ 15.13 30 Day Perf: 3.07 %
Volume (M): 1,248 52 Wk High: $ 15.16
Volume (M$): $ 18,880 52 Wk Avg: $14.78
Open: $15.15 52 Wk Low: $14.53



 Market Capitalization (Millions $) 219
 Shares Outstanding (Millions) 14
 Employees 97
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 201
 Cash Flow (TTM) (Millions $) 215
 Capital Exp. (TTM) (Millions $) 0

Merrimack Pharmaceuticals Inc
Merrimack Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of therapeutic agents for the treatment of cancer. The company was founded in 2000 and is headquartered in Cambridge, Massachusetts. It is focused on developing innovative therapies that can improve the lives of cancer patients, by disrupting tumor biology and delivering sustained clinical benefit.

Merrimack Pharmaceuticals develop drugs using a proprietary platform called the Merrimack Network Biology approach. This unique approach combines advanced biology and computational modeling to identify potential targets and pathways in the tumor microenvironment. The approach seeks to identify novel drug targets, better understand patient response, and develop more efficacious drug regimens.

The companyes pipeline is primarily focused on cancer indications, and it boasts several drug candidates in various stages of clinical development. Merrimackes flagship product candidate is MM-398, also known as enanoliposomal irinotecane or eOnivyde,e which was approved by the FDA for the treatment of metastatic pancreatic cancer in 201 It is the first and only FDA-approved therapy for patients with metastatic pancreatic cancer who have failed prior gemcitabine-based therapy.

The company other product candidates include MM-121, which targets HER3, and MM-141, which targets IGF-1R and HER Merrimackes candidates are designed to target multiple signal pathways, overriding resistance mechanisms that cancer cells can adopt, increasing the efficacy of the drugs and improving survival for patients.

Merrimack Pharmaceuticals has a team of experienced professionals, including scientists, clinicians, and business executives who bring expertise not only in oncology, but also in biotechnology, finance, and operations. The company has received multiple awards and has been recognized for its innovative approach to cancer drug development.

In recent years, Merrimack Pharmaceuticals conducted a strategic review of the company and concluded that the company would be better positioned to deliver value to shareholders through the strategic divestiture of its marketed product portfolio and development pipeline. In October 2017, Merrimack Pharmaceuticals announced the closure of their commercial operations to focus on oncology and clinical development of their promising pipeline.

In conclusion, Merrimack Pharmaceuticals Inc. has established itself as a leader in the pharmaceutical industry with its innovative approach to cancer drug development. With a diverse pipeline of products in clinical development for a variety of indications, Merrimack is poised to make significant strides in the treatment of cancer.


   Company Address: One Broadway Cambridge 2142 MA
   Company Phone Number: 720-8606   Stock Exchange / Ticker: NASDAQ MACK


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV        1.43% 
BMY   -1.46%    
LLY   -0.52%    
MRK   -2.46%    
TEVA   -5.49%    
VTRS   -2.75%    
• View Complete Report
   



Business Update

Merrimack Pharmaceuticals, Inc. to Dissolve and Provide Cash Liquidating Dividend

Published Mon, May 13 2024 5:29 AM UTC

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) has recently received stockholder approval for its Plan of Dissolution and subsequently declared a cash liquidating dividend of $15.10 per share. The company s Common Stock will continue trading on NASDAQ until May 17, 2024, after which it will be delisted. This article aims to ly present the factual information surrounding Merr...

Business Update

Merrimack Pharmaceuticals Receives Stockholder Approval for Dissolution Plan and Declares Cash Liquidating Dividend

Published Sun, May 12 2024 4:45 AM UTC

Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a renowned biopharmaceutical company based in Cambridge, MA, recently announced that its stockholders have overwhelmingly approved the adoption of a Plan of Dissolution. Following this decision, the company s Board of Directors declared a liquidating cash dividend of $15.10 per share of common stock. This press release sheds li...

Business Update

Merrimack Pharmaceuticals Announces Plan of Dissolution, Stockholder Approval, and Cash Liquidating Dividend

Published Sat, May 11 2024 4:24 AM UTC

In a recent announcement, Merrimack Pharmaceuticals, Inc. declared that its stockholders have overwhelmingly approved a Plan of Dissolution, marking a significant development for the company. Alongside this approval, the company s Board of Directors has declared a cash liquidating dividend of $15.10 per share. This article aims to outline the key facts surrounding these anno...

Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc Faces Operating Deficit in Third Quarter 2023, Raising Concerns Among Investors

As an avid investor and follower of the financial markets, I have been closely monitoring the recent financial results of Merrimack Pharmaceuticals Inc. The company's performance during the July to September 2023 reporting season has not shown any significant changes, as anticipated by investors. However, there is one aspect that has caught the attention of many: MACK's operating deficit.
During the same period, MACK's operating deficit stood at $-0.531 million, indicating a substantial loss. Although the company has not reported its revenue thus far, it is crucial to examine its business accomplishments in the context of previous quarters. Looking back at the third quarter of 2022, Merrimack Pharmaceuticals Inc recorded an operating deficit of $-0.504 million, which suggests a stagnancy or possibly even a slight worsening of their financial situation.

Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc Releases Fiscal Q2 2023 Numbers, Contributing to the Thriving Major Pharmaceutical Preparations Market



In the Major Pharmaceutical Preparations industry, several prominent companies have recently released their earnings reports. Alongside these industry leaders, Merrimack Pharmaceuticals Inc, a lesser-known organization, has announced its financial outcomes for the second quarter of 2023.
MACK, as they are commonly referred to, has reported an operating loss of -$0.569 million for the second quarter of 2023. This represents a decline compared to the operating loss of -$0.486 million reported in the same quarter of the previous year. The announcement of this operating loss aligns with the organization's current situation.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com